To order this detailed 370+ page report, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html
Key Inclusions
§
A detailed review of
the overall landscape of bispecific antibody therapeutics, including
information on drug developers, phase of development (marketed, clinical, and
preclinical / discovery) of the pipeline candidates, target antigen, type of
antibody format, mechanism of action, target disease indication(s), therapeutic
area, broader disease segment, route of administration, mode of administration
and patient segment.
§
A comprehensive list
of novel technology platforms that are either currently available or being
developed by various firms for the generation of bispecific antibody
therapeutics, along with detailed profiles of key technologies. The chapter
also includes an insightful competitiveness analysis, featuring a
three-dimensional bubble representation that highlights the key technologies
that are being used for the development of bispecific antibodies, taking into
consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above)
development activity based on the technology (in terms of the number of drugs
across different phases of development), number of partnerships established
related to the technology and size of the developer company. In addition, it
consists of a schematic world map representation, highlighting the geographical
locations of technology developers engaged in this domain.
§
Detailed profiles of
marketed and clinical stage (phase II and phase III) bispecific antibody
therapeutics. Each profile features an overview of the drug, details of the
developer, along with its financial performance, mechanism of action and
targets, dosage information, current clinical development status, development
process, as well as details on annual sales (wherever available).
§
Key takeaways from
the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis,
representing the distribution of the pipeline (on the basis of mechanisms of
action of product candidates) across different therapeutic areas and stages of
development, [B] a five-dimensional spider-web analysis, highlighting the most
popular mechanisms of action based on a number of relevant parameters,
including number of bispecific antibodies in early stage (phase I) and late
stage of development (phase II and above), number of ongoing clinical trials,
target therapeutic areas and the number of companies that are developing these
molecules, [C] a two-dimensional scattered plot competitiveness analysis, for
the various target combinations for clinical-stage bispecific antibodies and
[D] the chapter also includes an insightful summary representation using the
logos of different industry stakeholders, highlighting the distribution of
companies based on the company size.
§
An analysis of the
big biopharma players engaged in this domain, featuring a heat map based on
various parameters, such as number of bispecific antibody therapeutics under
development, target antigen, type of antibody format, mechanism of action and
target therapeutic area.
§
An analysis of recent
partnerships and collaboration agreements inked in this domain since 2016,
covering research collaborations, product and technology licensing agreements,
product development and commercialization agreements, manufacturing agreements,
mergers / acquisitions, joint ventures, product development agreements and
other deals.
§
A review on the key
steps involved and challenges associated with the manufacturing of bispecific
antibodies. In addition, it includes a list of contract manufacturing
organizations (CMOs) and contract research organizations (CROs). The chapter
also highlights the key considerations for bispecific antibody developers while
selecting a suitable CRO / CMO.
§
A clinical trial
analysis of ongoing and planned studies related to bispecific antibody
therapeutics, taking into consideration a number of relevant parameters,
including trial registration year, trial recruitment status, trial phase, trial
design, disease indication(s), focus therapeutic area, most active industrial
and non-industrial players, and geographical location of the trial.
§
A review of the key
promotional strategies that have been adopted by the developers of the marketed
bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed
comparison of both the drugs based on the information available on their
respective websites, such as patient support offerings, informative
downloadable content, and product visibility in scientific conferences.
§
A discussion on
important, industry-specific trends, key market drivers and challenges, under a
SWOT framework, featuring a qualitative Harvey ball analysis that highlights
the relative impact of each SWOT parameter on the overall market.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Autoimmune
Disorders
§ Eye
Disorders
§ Genetic
Disorders
§ Hematological
Malignancies
§ Infectious
Diseases
§ Inflammatory
Disorders
§ Skin
Disorders
§ Cytokines
Retargeting / Neutralization
§ Dual
Ligands Blocking
§ T-cell
Retargeting / Activation
§ Others
§ CD3
x CD19
§ CD30
x CD16A
§ Factor
IXa x Factor X
§ IL-1α
x IL-1β
§ IL-13
x IL-4
§ IL-17A
x Albumin
§ IL-17A
x IL-17F
§ Psl
x PcrV
§ VEGF-A
x ANG2
§ Others
§ Astra
Zeneca
§ Amgen
§ AbbVie
§ Affirmed
§ Affibody
§ Merck
§ Roche
§ Sanofi
§ Taisho
Pharmaceutical
§ North
America
§ Europe
§ Asia-Pacific
The report features
inputs from eminent industry stakeholders, according to whom this relatively
novel class of antibody therapeutics is likely to garner significant interest
among therapy developers and end users alike. The report includes detailed
transcripts of discussions held with the following experts:
§
Martin Steiner (Chief Executive Officer, Synimmune)
§
Ludger Große-Hovest (Chief Scientific Officer, Synimmune)
§
Jane Dancer (Chief Business Officer, F-Star)
§
Siobhan Pomeroy (Senior Director, Business Development,
Cytom X)
§
Yinjue Wang (Associate Director, Process Development,
Innovent Biologics)
To request sample pages, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html
Key Questions Answered
§
What are the key
technologies used for the development of bispecific antibodies?
§
What are the key
biological target combinations and antibody formats that are being explored for
bispecific antibody development?
§
Who are the leading
industry and non-industry players engaged in this market?
§
What kind of
partnership models are commonly adopted by bispecific antibody developers?
§
Which CMOs offer
services for manufacturing bispecific antibodies?
§
What are the
regulatory guidelines issued by different organizations related to the
development of bispecific antibodies?
§
What kind of
promotional strategies are being used by developers of marketed bispecific
antibody developers?
§
How is the current
and future market opportunity (related to bispecific antibodies) likely to be
distributed across key market segments?
You may also be interested in the following titles:
Global Preventive
Vaccines Market, 2020-2030
Endocannabinoid System
Targeted Therapeutics Market, 2019-2030
Antibody Contract
Manufacturing Market, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
